Policymakers may need to choose from a menu of options that include value-based pricing, outcome-based payment arrangements, warranties, subscription-based insurance models and a federal “carve-out” coverage benefit to ensure the government can pay for incoming expensive gene therapies, says a new white paper published Tuesday (April 23) by the Institute for Clinical and Economic Review (ICER) in collaboration with the NEW Drug Development Paradigms (NEWDIGS) program at the Tufts Medical Center. ICER and NEWDIGS stress that policymakers cannot rely on...